Arbutus Biopharma Corporation (ABUS) Revenue by Segment & Business Profile
License was 62.3% of Arbutus Biopharma Corporation's revenue across the 4 lines it reports, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ABUSArbutus Biopharma CorporationFollow ABUS — free
—
Price chart with a free account
- Market cap
- 831.0M
- P/E TTM
- 5.3
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
What the company does
Arbutus Biopharma Corporation is a biotechnology company in the healthcare sector. In its SEC filings it reports 4 business lines: License (62%), Collaboration And Contracts (20%), Non Cash Royalty (18%), Other (0%). Trailing twelve-month revenue: $181.7 million as of 2026-06-30.
Roles we read
from the filings, not the sector label- Clinical-stage developer
Arbutus Biopharma Corporation — questions
- What does Arbutus Biopharma Corporation do?
- Arbutus Biopharma Corporation is a biotechnology company in the healthcare sector. In its SEC filings it reports 4 business lines: License (62%), Collaboration And Contracts (20%), Non Cash Royalty (18%), Other (0%). Trailing twelve-month revenue: $181.7 million as of 2026-06-30.
- How does Arbutus Biopharma Corporation make money?
- By the lines it reports in its SEC filings: License 62.3%, Collaboration And Contracts 19.9%, Non Cash Royalty 17.7%, Other 0.1% of revenue.
Every figure on this page comes from Arbutus Biopharma Corporation's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.